Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Pappadopulos

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Psychiatry|July 17, 2012
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trialsElizabeth Pappadopulos, John W Newcomer, Sheela Kolluri
The International Journal of Neuropsychopharmacology|March 15, 2011
Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled studyEduard Vieta, Elizabeth Pappadopulos, Francine S Mandel, et al.
Schizophrenia Research|February 5, 2009
Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidolPhilip D Harvey, Elizabeth Pappadopulos, Ilise Lombardo, et al.
Pediatrics|May 30, 2012
Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and managementPenelope Knapp, Alanna Chait, Elizabeth Pappadopulos, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 13, 2012
Early prediction of clinical and functional outcome in schizophreniaOfer Agid, Cynthia O Siu, Elizabeth Pappadopulos, et al.
Current Medical Research and Opinion|November 1, 2016
A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorderMichael Thase, Yuko Asami, Dalia Wajsbrot, et al.
Journal of Clinical Psychopharmacology|April 24, 2013
Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophreniaKeming Gao, Elizabeth Pappadopulos, Onur N Karayal, et al.
Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal De L'Academie Canadienne De Psychiatrie De L'Enfant Et De L'Adolescent|April 9, 2008
Pharmacotherapy of aggression in children and adolescents: efficacy and effect sizeElizabeth Pappadopulos, Sophie Woolston, Alanna Chait, et al.
Neuropsychiatric Disease and Treatment|November 9, 2016
Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims dataCaitlyn T Solem, Ahmed Shelbaya, Yin Wan, et al.
Journal of Child and Adolescent Psychopharmacology|April 28, 2012
Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorderDaniel J Coletti, Elizabeth Pappadopulos, Nikki J Katsiotas, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Psychiatry|July 17, 2012
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trialsElizabeth Pappadopulos, John W Newcomer, Sheela Kolluri
The International Journal of Neuropsychopharmacology|March 15, 2011
Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled studyEduard Vieta, Elizabeth Pappadopulos, Francine S Mandel, et al.
Schizophrenia Research|February 5, 2009
Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidolPhilip D Harvey, Elizabeth Pappadopulos, Ilise Lombardo, et al.
Pediatrics|May 30, 2012
Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and managementPenelope Knapp, Alanna Chait, Elizabeth Pappadopulos, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 13, 2012
Early prediction of clinical and functional outcome in schizophreniaOfer Agid, Cynthia O Siu, Elizabeth Pappadopulos, et al.
Current Medical Research and Opinion|November 1, 2016
A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorderMichael Thase, Yuko Asami, Dalia Wajsbrot, et al.
Journal of Clinical Psychopharmacology|April 24, 2013
Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophreniaKeming Gao, Elizabeth Pappadopulos, Onur N Karayal, et al.
Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal De L'Academie Canadienne De Psychiatrie De L'Enfant Et De L'Adolescent|April 9, 2008
Pharmacotherapy of aggression in children and adolescents: efficacy and effect sizeElizabeth Pappadopulos, Sophie Woolston, Alanna Chait, et al.
Neuropsychiatric Disease and Treatment|November 9, 2016
Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims dataCaitlyn T Solem, Ahmed Shelbaya, Yin Wan, et al.
Journal of Child and Adolescent Psychopharmacology|April 28, 2012
Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorderDaniel J Coletti, Elizabeth Pappadopulos, Nikki J Katsiotas, et al.
Pageof 4